Please provide your email address to receive an email when new articles are posted on . Compared with men, women having heart surgery are less likely to receive guideline-directed care and more likely ...

New guidelines and advocacy enhance myasthenia gravis treatment access, promoting proactive management and improved insurance coverage for diverse patient populations. There are key systemic factors ...

According to Ian Neeland, MD, strategies like pharmacist-led counseling, patient education programs, and patient assistance initiatives are key to addressing therapeutic inertia. Therapeutic inertia ...

Please provide your email address to receive an email when new articles are posted on . Disease-specific quality of life and symptoms improved in undiagnosed COPD/asthma with either pulmonologist- or ...

Researchers have found that prescribing guideline-directed medical treatment (GDMT), regardless of the number of medications, can improve survival rates in patients 90 years of age and older following ...

Timely diagnosis and proper management of peripheral artery disease (PAD), including coordinated care from a multispecialty team, are essential to help prevent amputation and other cardiovascular ...

About The Study: In this randomized clinical trial including 103 American Indian patients, a telephone-based strategy of remote initiation and titration for outpatients with heart failure with reduced ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced the launch of a new program specifically geared towards using ...

There are a growing number of studies of integrative therapies for the management of cancer fatigue. Mindfulness-based interventions (MBIs) are among those with the strongest evidence base both during ...

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm ...

Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with hypomethylating agents (HMAs), according to results published in Blood Neoplasia. The ...